1025716-99-7

Basic information

• Product Name: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate
• Synonyms: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate;Benzoic acid,3-[(aMinoiMinoMethyl)aMino]-4-Methyl-,Methyl ester,nitrate(1:1);Methyl 3-guanidino-4-Methylbenzoate Mononitrate;3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid methyl ester nitrate;3-[(aminoiminomethyl)amino]-4-methyl-benzoic acid;((aminoiminomethyl)amino)-4-methylbenzoic acid methyl ester nitrate;methyl 3-guanidino-4-methylbenzoate nitrate
• CAS NO: 1025716-99-7
• Molecular Formula: C₁₀H₁₃N₃O₂*HNO₃
• Molecular Weight: 270.24196
• Product Categories: Intermediates
• Mol File: 1025716-99-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate(1025716-99-7)
• EPA Substance Registry System: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate(1025716-99-7)

Safety Data

• Hazardous Substances Data: 1025716-99-7(Hazardous Substances Data)

Usage

General Description

3-[(AminoiminoMethyl)amino]-4-methylbenzoic acid methyl ester mononitrate, also known as Mibefradil, is a chemical compound that acts as a calcium channel blocker. It is used in the treatment of hypertension and angina pectoris and works by inhibiting the influx of calcium ions into smooth muscle cells and cardiac myocytes. This leads to relaxation of the blood vessels and a reduction in cardiac workload, ultimately lowering blood pressure and improving myocardial oxygen supply. Mibefradil has been found to be effective in the treatment of various cardiovascular conditions, but it has been discontinued in some countries due to potential side effects and drug interactions.

Upstream product

• 420-04-2 CYANAMID 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 

Downstream Products

• 917392-54-2 methyl 4-methyl-3 -[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzoate 
• 1079911-30-0 {5-[5-(3-difluoromethoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-2-methyl-phenyl}-(4-pyridin-3-yl-pyrimidin-2-yl)-amine 
• 1079904-27-0 [2-methyl-5-(6-trifluoromethyl-1H-benzoimidazol-2-yl)-phenyl]-(4-pyridin-3-yl-pyrimidin-2-yl)-amine 
• 641569-94-0 4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoic acid 
• 923288-95-3 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide hydrochloride 
• 641571-10-0 nilotinib 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF NILOTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention relates to an improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof, with high purity and yields.

COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR alpha and PDGFR beta kinases